Genomics firm GeneDx reports a 40.48% one-month decline in shares, underperforming broader small-cap growth benchmarks in Q1 2026.
GeneDx Holdings Corp. (NASDAQ:WGS) closed at $38.94 on May 13, 2026, marking a 40.48% drop over the past month. The genomics company, specializing in pediatric and rare disease diagnostics, saw its shares decline despite operational improvements noted by investors.
The Polen 5Perspectives Small Growth Strategy, which holds WGS, returned 3.3% gross in Q1 2026, outperforming the Russell 2000 Growth Index’s -2.8% return. However, GeneDx’s stock lagged, with a 38.78% loss over the past 52 weeks amid broader market volatility driven by AI disruption fears, private credit concerns, and geopolitical risks.
Investors have shifted focus toward macroeconomic uncertainties, including inflation and interest rate expectations, which have pressured small-cap stocks despite strong early-quarter performance.